Literature DB >> 31059866

A validated method for the quantification of mitragynine in sixteen commercially available Kratom (Mitragyna speciosa) products.

Kristen L Fowble1, Rabi A Musah2.   

Abstract

The recent rise in the recreational use of plant-based "legal highs" has prompted the development of methods for the identification of the bulk material, and quantification of their psychoactive components. One of these plants is Mitragyna speciosa, commonly referred to as Kratom. While traditional use of this plant was primarily for medicinal purposes, there has been a rise in its recreational use, and as a self-prescribed medication for opioid withdrawal. Although Kratom contains many alkaloids, mitragynine and 7-hydroxymitragynine are unique psychoactive biomarkers of the species, and are responsible for its psychoactive effects. A rapid validated method for the quantification of mitragynine in Kratom plant materials by direct analysis in real time-high-resolution mass spectrometry (DART-HRMS) is presented. It has a linear range of 5-100 μg mL-1, and a lower limit of quantification of 5 μg mL-1. The protocol was applied to determination of the mitragynine content of 16 commercially available Kratom plant products purchased online. The mitragynine amounts in these materials ranged from 2.76 to 20.05 mg g-1 of dried plant material. The utilization of DART-HRMS affords a mechanism not only for the preliminary identification of bulk plant material as being M. speciosa-derived (with no sample preparation required), but also provides the opportunity to quantify its psychoactive components using the same technique.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Direct analysis in real time-high-resolution mass spectrometry; Kratom; Mitragyna speciosa; Mitragynine; Quantification

Mesh:

Substances:

Year:  2019        PMID: 31059866     DOI: 10.1016/j.forsciint.2019.04.009

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  6 in total

1.  Kratom Use in the US: Both a Regional Phenomenon and a White Middle-Class Phenomenon? Evidence From NSDUH 2019 and an Online Convenience Sample.

Authors:  Jeffrey M Rogers; Kirsten E Smith; Justin C Strickland; David H Epstein
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

2.  Acute, Sublethal, and Developmental Toxicity of Kratom (Mitragyna speciosa Korth.) Leaf Preparations on Caenorhabditis elegans as an Invertebrate Model for Human Exposure.

Authors:  Samantha Hughes; David van de Klashorst; Charles A Veltri; Oliver Grundmann
Journal:  Int J Environ Res Public Health       Date:  2022-05-22       Impact factor: 4.614

3.  Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Kelly E Dunn; Oliver Grundmann; Christopher R McCurdy; Destiny Schriefer; David H Epstein
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

4.  Kratom (Mitragyna speciosa) Validation: Quantitative Analysis of Indole and Oxindole Alkaloids Reveals Chemotypes of Plants and Products.

Authors:  Preston K Manwill; Laura Flores-Bocanegra; Manead Khin; Huzefa A Raja; Nadja B Cech; Nicholas H Oberlies; Daniel A Todd
Journal:  Planta Med       Date:  2022-04-25       Impact factor: 3.007

5.  Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Destiny Schriefer; Oliver Grundmann
Journal:  Drug Alcohol Depend       Date:  2021-06-25       Impact factor: 4.852

6.  Detection and Quantification of Psychoactive N,N-Dimethyltryptamine in Ayahuasca Brews by Ambient Ionization High-Resolution Mass Spectrometry.

Authors:  Megan I Chambers; Meghan G Appley; Cameron M Longo; Rabi A Musah
Journal:  ACS Omega       Date:  2020-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.